希玛眼科二零二三年中期报告

Contents目錄 Corporate Information公司資料 Financial Highlights財務概要 Management Discussion and Analysis管理層討論及分析 Condensed Consolidated Interim Statement of Comprehensive Income簡明綜合中期全面收益表 Condensed Consolidated Interim Statement of Financial Position簡明綜合中期財務狀況表 Condensed Consolidated Interim Statement of Changes in Equity簡明綜合中期權益變動表 Condensed Consolidated Interim Statement of Cash Flows簡明綜合中期現金流量表 Notes to the Condensed Consolidated Interim Financial Information簡明綜合中期財務資料附註 Report on Review of Interim Financial Information中期財務資料的審閱報告 Other Information其他資料 Corporate Information公司資料 BOARD OF DIRECTORSExecutive Directors 董事會 Dr. LAM Shun Chiu Dennis(Chairman and Chief Executive Officer)Ms. LI XiaotingDr. LEE Yau Wing VincentMr. LI Chunshan (stepped down with effect from 3 July 2023) 林順潮醫生（主席兼行政總裁）李肖婷女士李佑榮醫生李春山先生（自2023年7月3日起卸任） Independent Non-executive DirectorsDr. Rex AUYEUNG Pak-kuen(Vice Chairman) 獨立非執行董事歐陽伯權博士（副主席） 李國棟醫生（於2023年5月30日退任）馬照祥先生陳智亮先生（於2023年5月30日退任）梁安妮女士（於2023年5月30日退任）葉澍堃先生殷可先生（自2023年7月3日起獲委任） Dr. LI Kwok Tung Donald (retired on 30 May 2023)Mr. MA Andrew Chiu CheungMr. CHAN Chi Leong (retired on 30 May 2023)Ms. BENTLEY Annie Liang (retired on 30 May 2023)Mr. IP Shu Kwan StephenMr. YIN Ke (appointed with effect from 3 July 2023) 董事會委員會審核委員會馬照祥先生（主席）葉澍堃先生殷可先生 BOARD COMMITTEESAudit Committee Mr. MA Andrew Chiu Cheung(Chairperson)Mr. IP Shu Kwan StephenMr. YIN Ke 薪酬委員會葉澍堃先生（主席）李肖婷女士馬照祥先生 Remuneration CommitteeMr. IP Shu Kwan Stephen(Chairperson)Ms. LI XiaotingMr. MA Andrew Chiu Cheung 提名委員會歐陽伯權博士（主席）馬照祥先生殷可先生 Nomination CommitteeDr. AUYEUNG Rex Pak-kuen(Chairperson)Mr. MA Andrew Chiu CheungMr. YIN Ke 授權代表李肖婷女士陳華平先生 AUTHORIZED REPRESENTATIVESMs. LI Xiaoting Mr. CHAN Wa Ping COMPANY SECRETARYMr. CHAN Wa Ping 公司秘書陳華平先生 核數師羅兵咸永道會計師事務所執業會計師註冊公眾利益實體核數師香港中環太子大廈22樓 AUDITOR PricewaterhouseCoopersCertified Public AccountantsRegistered Public Interest Entity Auditor22/F, Prince’s BuildingCentralHong Kong REGISTERED OFFICE 註冊辦事處Cricket Square, Hutchins DriveP.O. Box 2681 Grand CaymanKY1-1111Cayman Islands Cricket Square, Hutchins DriveP.O. Box 2681 Grand CaymanKY1-1111Cayman Islands 香港主要營業地點及總部 PRINCIPAL PLACE OF BUSINESS AND HEADOFFICE IN HONG KONG 香港畢打街1–3號中建大廈1535室 Suite 1535, Central Building1–3 Pedder StreetHong Kong 股份過戶登記總處Conyers Trust Company (Cayman) Limited PRINCIPAL SHARE REGISTRARConyers Trust Company (Cayman) Limited Cricket Square, Hutchins DriveP.O. Box 2681Grand Cayman, KY1-1111Cayman Islands Cricket Square, Hutchins DriveP.O. Box 2681Grand Cayman, KY1-1111Cayman Islands 香港股份過戶登記分處香港中央證券登記有限公司香港灣仔皇后大道東183號合和中心17樓1712–1716號舖 HONG KONG BRANCH SHARE REGISTRARComputershare Hong Kong Investor Services Limited Shops 1712–1716, 17th FloorHopewell Centre183 Queen’s Road EastWanchaiHong Kong Corporate Information公司資料 PRINCIPAL BANKERS 主要往來銀行 The Bank of East Asia, LimitedBank of China (Hong Kong) LimitedBank of Communications Co., Ltd.Industrial and Commercial Bank of China LimitedThe Hongkong and Shanghai Banking Corporation Limited 東亞銀行有限公司中國銀行（香港）有限公司交通銀行股份有限公司中國工商銀行股份有限公司香港上海滙豐銀行有限公司 LEGAL ADVISOR ON HONG KONG LAWSFangda Partners 香港法律顧問方達律師事務所香港中環康樂廣場8號交易廣場1期26樓 26th Floor, One Exchange Square8 Connaught PlaceCentral, Hong Kong 公司網站www.cmereye.com COMPANY WEBSITEwww.cmereye.com 股份代號03309 STOCK CODE03309 1該項目並非香港財務報告準則（「香港財務報告準則」）下計量表現的指標，惟獲管理層從營運角度廣泛應用於監控公司業務表現。其未必可與其他公司呈列的類似計量指標作比較。 1This is not a measure of performance under Hong KongFinancial Reporting Standards (“HKFRSs”), but is widely usedby management for monitoring business performance ofa company from an operational perspective. It may not becomparable to similar measures presented by other companies. Management Discussion and Analysis管理層討論及分析 業務回顧 BUSINESS REVIEWOverview 概覽 截至2023年6月30日止六個月（「2023年上半年」），本集團的醫療服務業務與去年同期相比強勁反彈。憑藉我們在提供優質醫療服務方面的美譽，於2023年上半年，我們核心醫療服務的收益（包括提供眼科服務、提供牙科及其他醫療服務以及銷售視力輔助產品）由去年同期的660.8百萬港元增長40.9%至930.8百萬港元，創下歷史新高。來自醫療服務的收益大幅增加乃由於香港及中國內地在COVID-19後對眼科及牙科服務的需求均展現強勁反彈以及亦因港深兩地通關所致。 The Group had a strong rebound in our medical servicebusiness for the six months ended 30 June 2023 (“1H2023”)compared with the same period last year. Leveraging onour strong reputation in providing quality medical services,our core medical service revenue (comprising provisionof ophthalmic services, provision of dental and othermedical services and sales of vision aid products) increasedby 40.9%, reaching a record high of HK$930.8 million in1H2023 from HK$660.8 million for the same period lastyear. The significant increase in revenue generated frommedical service is due to the strong post COVID-19 reboundin demand for both ophthalmic and dental services inboth Hong Kong and Mainland China, and also due to thereopening of the border between Hong Kong and Shenzhen. Despite the reduction in revenue generated from sale ofCOVID-19 related medical consumables to HK$19.4 million in1H2023 from HK$220.7 million for the same period last year,our diverse portfolio of businesses was resilient and